SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid CardiomyopathyAldostefano Porcari, Marianna Fontana, Marco Canepa et al.|Journal of the American College of Cardiology|2024Cited by 137
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <scp>AC‐TIVE</scp> study, an <scp>Italian nationwide survey</scp>Marco Merlo, Gianfranco Sinagra, Linda Pagura et al.|European Journal of Heart Failure|2022Cited by 91
Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosisAldostefano Porcari, Marco Merlo, Maddalena Rossi et al.|European Journal of Heart Failure|2022Cited by 69
Low QRS Voltages in Cardiac AmyloidosisAlberto Cipriani, Claudio Rapezzi, Laura De Michieli et al.|JACC CardioOncology|2022Cited by 67
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization — the first insight from the AC-TIVE StudyMarco Merlo, Gianfranco Sinagra, Aldostefano Porcari et al.|European Journal of Preventive Cardiology|2021Cited by 46